This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Olivotto, I. A. Articles by Ragaz, J. Search for Related Content PubMed PubMed Citation Articles by Olivotto, I. A. Articles by Ragaz, J. Social Bookmarking                            What's this?

Long-Term Survival of Patients With Supraclavicular Metastases at Diagnosis of Breast Cancer

From the Breast Cancer Outcomes Unit and Radiation and Systemic Therapy Programs of the British Columbia Cancer Agency, Victoria, and University of British Columbia, Vancouver, British Columbia, Canada.

Address reprint requests to I.A. Olivotto, MD, British Columbia Cancer Agency-Vancouver Island Centre, 2410 Lee Ave, Victoria, British Columbia, Canada, V8R 6V5; email: iolivott{at}bccancer.bc.ca.

Background: Patients with supraclavicular metastases at diagnosis of breast cancer were classified between 1987 and 2002 as having stage M₁ breast cancer according to the tumor-node-metastasis (TNM) system. The 2003 edition of the TNM staging guidelines has classified such patients as having stage IIIC disease. To determine relative prognosis, we compared long-term survival in a population-based cohort of patients with isolated supraclavicular metastases (nodal-M₁) to outcomes of patients with stage IIIB or M₁ (other) disease at presentation.

Materials and Methods: Among patients with breast cancer and known tumor stage referred to the British Columbia Cancer Agency from 1976 to 1985, 336 IIIB, 233 M₁, and 51 nodal-M₁ patients were identified. Actuarial overall and breast cancer–specific survival rates were determined to 20 years.

Results: Overall survival at 20 years was 13.2% for nodal-M₁ cases (95% confidence interval [CI], 5% to 26%), 9.4% for IIIB cases (95% CI, 6% to 14%), and 1.3% for M₁ (other) cases (95% CI, 0.4% to 3.5%; log-rank P < .0005). Overall survival was similar between nodal-M₁ and IIIB cases (P = .27). Breast cancer–specific survival at 20 years was 24.1% for nodal-M₁ cases (95% CI, 13% to 37%), 30.2% for IIIB cases (95% CI, 23% to 38%), and 3.9% for M₁ (other) cases (95% CI, 2% to 8%; log-rank P < .0005). Breast cancer–specific survival was significantly different for nodal-M₁ cases compared with either IIIB or M₁ (other) cases (P = .008 for both).

Conclusion: Patients with supraclavicular metastases at diagnosis have significantly better outcomes than patients with M₁ (other) disease and overall survival similar to patients with IIIB disease. Reclassification as stage IIIC is appropriate for patients with breast cancer who present with supraclavicular nodal metastases alone.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				A. Ardavanis, A. Scorilas, D. Tryfonopoulos, G. Orphanos, I. Missitzis, M. Karamouzis, M. Chrysochoou, A. Sotiropoulou, N. Arnogiannaki, G. Ioannidis, et al. Multidisciplinary therapy of locally far-advanced or inflammatory breast cancer with fixed perioperative sequence of epirubicin, vinorelbine, and Fluorouracil chemotherapy, surgery, and radiotherapy: long-term results. Oncologist, June 1, 2006; 11(6): 563 - 573. [Abstract] [Full Text] [PDF]

				M. Panades, I. A. Olivotto, C. H. Speers, T. Shenkier, T. A. Olivotto, L. Weir, S. J. Allan, and P. T. Truong Evolving Treatment Strategies for Inflammatory Breast Cancer: A Population-Based Survival Analysis J. Clin. Oncol., March 20, 2005; 23(9): 1941 - 1950. [Abstract] [Full Text] [PDF]

				F. Andre, K. Slimane, T. Bachelot, A. Dunant, M. Namer, A. Barrelier, O. Kabbaj, J. P. Spano, H. Marsiglia, R. Rouzier, et al. Breast Cancer With Synchronous Metastases: Trends in Survival During a 14-Year Period J. Clin. Oncol., August 15, 2004; 22(16): 3302 - 3308. [Abstract] [Full Text] [PDF]

				T. Shenkier, L. Weir, M. Levine, I. Olivotto, T. Whelan, and L. Reyno Clinical practice guidelines for the care and treatment of breast cancer: 15. Treatment for women with stage III or locally advanced breast cancer Can. Med. Assoc. J., March 16, 2004; 170(6): 983 - 994. [Abstract] [Full Text] [PDF]